← Back to headlines
BridgeBio Settles Patent Dispute with Pfizer
BridgeBio Pharmaceuticals saw gains after reaching a settlement in its patent dispute with Pfizer regarding the drug Vyndamax.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
